Targets › CD19
269 programs from 160 companies in 557 trials: 344 Phase 1, 170 Phase 2, 37 Phase 3, 6 Phase 4; Oncology, Immunology, Neurology; next expected readout Nov 2026.
Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. (UniProt, P15391)
Open in Phaseline: the race on CD19, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amgen | Inebilizumab B-lymphocyte antigen CD19 binding agent | CD19 | Phase 4 | Neuromyelitis Optica Spectrum Disorder; IgG4 Related Disease; Myasthenia Gravis; Autoimmune Hepatitis … | Apr 2027 |
| Zenas BioPharma (USA) | Obexelimab B-lymphocyte antigen CD19 inhibitor; Low affinity immunoglobulin gamma Fc region receptor II-b inhibitor | CD19, FCGR2B | Phase 3 | Warm Autoimmune Hemolytic Anemia; IgG4 Related Disease; Relapsing Multiple Sclerosis; Systemic Lupus Erythematosus | Dec 2026 |
| ADC Therapeutics | Loncastuximab Tesirine B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | Relapsed Diffuse Large B-Cell Lymphoma; B-Cell Non-Hodgkin Lymphoma; Relapsed or Refractory Large B-cell Lymphoma; Relapsed Mantle Cell Lymphoma … | Mar 2027 |
| Novartis | Tisagenlecleucel (CTL019) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | B-cell Acute Lymphoblastic Leukemia; Follicular Lymphoma (FL); Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program; B-Cell Acute Lymphoblastic Leukemia … | Mar 2027 |
| Incyte | Tafasitamab B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma; Hematologic Malignancies … | Apr 2027 |
| AstraZeneca | AZD0120 BCMA/CD19 dual CAR T cell therapy | BCMA, CD19 | Phase 3 | Relapsed Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma (NDMM); Newly Diagnosed Multiple Myeloma; Relapsed/Refractory Multiple Myeloma … | Oct 2027 |
| Amgen | Blinatumomab T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent | CD3E, CD3G, CD3D, CD19 | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL); B Precursor Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus; B Cell Precursor Acute Lymphoblastic Leukemia … | Oct 2027 |
| AstraZeneca | surovatamig (AZD0486) Bispecific monoclonal antibody targeting CD20 and CD3E | CD19, CD3E, CD20 | Phase 3 | Large B-cell Lymphoma; Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV; Untreated Follicular Lymphoma; B-cell Non-Hodgkin Lymphoma … | Jan 2028 |
| Lyell Immunopharma | Rondecabtagene autoleucel (ronde-cel) Dual-targeting CAR T-cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 3 | Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma | Dec 2028 |
| Gilead Sciences | KITE-753 Anti-CD19 CAR-T cell therapy | CD19 | Phase 3 | Relapsed or Refractory Large B-cell Lymphoma; Relapsed and/or Refractory B-cell Lymphoma | Feb 2030 |
| Gilead Sciences | Axicabtagene Ciloleucel B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | Relapsed/Refractory Follicular Lymphoma; High-risk Large B-cell Lymphoma (LBCL); Lymphoma, B-Cell; B-Cell Lymphoma Refractory … | Oct 2030 |
| Tanabe Pharma | Inebilizumab (MT-0551) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | Systemic Sclerosis | – |
| KK Women's and Children's Hospital | Anti-CD19 CAR T-cells CD19-directed chimeric antigen receptor (CAR) T-cell therapy | CD19 | Phase 2 | Lymphoblastic Leukemia | Dec 2026 |
| Zhejiang University | CD19/CD22 CAR-T cells Bispecific CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 2 | Large B-Cell Lymphoma (LBCL); ALL | Dec 2026 |
| Beijing Tongren Hospital | CD19/CD22-bispecific CAR-T cells bispecific CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 2 | B-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| Juventas Cell Therapy | CNCT19 anti-CD19 CAR-T cell therapy | CD19 | Phase 2 | Non-Hodgkin's Lymphoma; Relapsed or Refractory Acute Lymphoblastic Leukemia; B-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| Chi Kong Li | CUCART19 anti-CD19 chimeric antigen receptor modified T-cell therapy | CD19 | Phase 2 | Lymphoma, Nonhodgkin | Dec 2026 |
| Shanghai Ming Ju Biotechnology | Relma-cel CD19-targeted CAR T cells | CD19 | Phase 2 | Non-Hodgkin Lymphoma; Relapsed or Refractory B-cell Lymphoma; B-cell Non Hodgkin Lymphoma; CNS Lymphoma … | Dec 2026 |
| Mitchell Cairo | alpha beta depletion (α/β CD3+/CD19+ cell depletion) Selective depletion of alpha/beta T cells and CD19+ B cells from donor stem cells for allo | CD3E, CD19 | Phase 2 | Acute Leukemia | Dec 2026 |
| Miltenyi Biomedicine | zamtocabtagene autoleucel (MB-CART2019.1) CD19-directed CAR-T cell therapy | CD19 | Phase 2 | Refractory Diffuse Large B Cell Lymphoma (DLBCL); DLBCL - Diffuse Large B Cell Lymphoma; B-Cell Neoplasm; Diffuse Large B-cell Lymphoma … | Dec 2026 |
| Liping Dou | CD22/CD19 CAR-T cell immunotherapy Dual-targeted CAR-T cell therapy against CD19 and CD22 | CD22, CD19 | Phase 2 | Lymphoma | Jan 2027 |
| Sun Yat-sen University | Relmacabtagene Autoleucel Anti-CD19 CAR-T cell therapy | CD19 | Phase 2 | Large B Cell Diffuse Lymphoma | Jan 2027 |
| National University of Malaysia | autologous CD19 CAR-T cells CAR-T cell therapy targeting CD19+ B cells | CD19 | Phase 2 | Relapsed B Acute Lymphoblastic Leukaemia; Systemic Lupus Erythematous (SLE) | Jan 2027 |
| City of Hope Medical Center | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes CAR-T cell expressing CD19-targeting chimeric antigen receptor with CD28 and CD3-zeta co-s | CD19 | Phase 2 | Recurrent Mantle Cell Lymphoma | Feb 2027 |
| Daihong Liu | CD22/CD19 CAR-T cell immunotherapy CAR-T cell therapy targeting CD22 and CD19 | CD22, CD19 | Phase 2 | Lymphoma | Mar 2027 |
| Kyverna Therapeutics | KYV-101 anti-CD19 chimeric antigen receptor T-cell therapy | CD19 | Phase 2 | Multiple Sclerosis, Primary Progressive; Myasthenia Gravis; Idiopathic Inflammatory Myopathies | Apr 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | Autologous CD19-CAR T cells anti-CD19 CAR-T cell therapy | CD19 | Phase 2 | Acute Lymphoblastic Leukemia ALL; B-cell Non-Hodgkin Lymphoma | Apr 2027 |
| Beijing Yongtai Ruike Biotechnology Company | CAR-T-19 cell injection anti-CD19 chimeric antigen receptor T cell therapy | CD19 | Phase 2 | Relapsed B-cell Acute Lymphoblastic Leukemia | Apr 2027 |
| ImmunityBio | CD19 t-haNK CAR-T cell therapy targeting CD19 | CD19 | Phase 2 | Relapsed B-Cell Non Hodgkin Lymphoma | May 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | CAR-T cells (single-target or dual-target directed against CD19, CD20, and/or CD CAR-T cell therapy targeting CD19, CD20, and/or CD22 | CD19, CD20, CD22 | Phase 2 | Relapsed or Refractory Aggressive B-cell Lymphoma | May 2027 |
| University Medical Center Groningen | ARI-0001 CD19-directed CAR T-cell therapy | CD19 | Phase 2 | NHL | Jun 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | CD19 targeted CAR T Cell Therapy CD19-directed CAR-T cell therapy | CD19 | Phase 2 | Diffuse Large-Cell Lymphoma | Jun 2027 |
| Johns Hopkins All Children's Hospital | TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation TCR alpha beta T-cell and CD19 B-cell depleted haploidentical hematopoietic cell transplan | TCRA, TCRB, CD19 | Phase 2 | Hemoglobinopathy (Disorder); Primary Immune Deficiency Disorders | Jun 2027 |
| Gilead Sciences | Brexucabtagene Autoleucel (X19) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 2 | Relapsed/Refractory Mantle Cell Lymphoma; Mantle Cell Lymphoma; B-Cell Lymphoblastic Leukemia; Recurrent Mantle Cell Lymphoma … | Jul 2027 |
| Bristol-Myers Squibb | CC-97540 CD19-targeted CAR T cells | CD19 | Phase 2 | Lupus Erythematosus, Systemic; Multiple Sclerosis; Systemic Lupus Erythematosus; Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Jul 2027 |
| The First Affiliated Hospital of Soochow University | CD22/CD19 CAR-T cells Dual-target CAR-T cells directed against CD22 and CD19 with 4-1BB co-stimulatory molecule | CD22, CD19 | Phase 2 | B-cell Acute Lymphoblastic Leukemia | Jul 2027 |
| Daihong Liu | Polymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoC CAR-T cell therapy delivering dual-targeting CD19/CD20 CAR mRNA via polymer-lipid nanopart | CD19, CD20 | Phase 2 | B-cell Lymphoma Refractory | Aug 2027 |
| Chinese PLA General Hospital | Anti-BCMA-CD19 CAR-T cells Dual-target CAR-T cell therapy targeting CD19 and BCMA antigens | BCMA, CD19 | Phase 2 | IgG4 Related Disease | Sep 2027 |
| Autolus | Obecabtagene Autoleucel B-lymphocyte antigen CD19 binding agent | CD19 | Phase 2 | Lupus Nephritis; Systemic Lupus Erythematosus; Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia; Progressive Multiple Sclerosis … | Sep 2027 |
| Fate Therapeutics | FT819 allogeneic CAR-T cells targeting CD19 | CD19 | Phase 2 | Lupus Nephritis; Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV); Lymphoma, B-Cell | Sep 2027 |
| Allogene Therapeutics | cemacabtagene ansegedleucel allogeneic CAR T cell therapy targeting CD19 | CD19 | Phase 2 | Large B-cell Lymphoma | Dec 2027 |
| Peking University People's Hospital | BCMA-CD19 CAR-T therapy Dual-targeted CAR-T cell therapy against BCMA and CD19 | TNFRSF17, CD19 | Phase 2 | Systemic Lupus Erythematosus | Dec 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | CD19&CD22 bispecific CAR-T cells Bispecific CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 2 | B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoblastic Leukemia/Lymphoma | Dec 2027 |
| The First Affiliated Hospital of Soochow University | CD19-CART CD19-directed chimeric antigen receptor T-cell therapy | CD19 | Phase 2 | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Dec 2027 |
| iCell Gene Therapeutics | ICG318 BCMA-CD19 dual-targeting CAR-T cells with IL-15/IL-15 sushi domain | TNFRSF17, CD19, BCMA | Phase 2 | Systemic Lupus Erythematosus (SLE); Inflammatory Myopathy | Dec 2027 |
| Bristol-Myers Squibb | Lisocabtagene Maraleucel B-lymphocyte antigen CD19 binding agent | CD19 | Phase 2 | Lymphoma | Jan 2028 |
| Copenhagen University Hospital, Rigshospitalet | iDLI (innate donor lymphocyte infusion) TCRαβ/CD19 depleted donor lymphocyte infusion enriched for NK cells (>10e7 cells/kg) and T | TRBC1, TRBC2, CD19 | Phase 2 | AML/MDS | Jan 2028 |
| Health Institutes of Turkey | Talikabtagene Autoleucel Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy | CD19 | Phase 2 | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) | Feb 2028 |
| King Hussein Cancer Center | MB-CART19.1 CAR-T cell therapy targeting CD19 | CD19 | Phase 2 | Non-Hodgkin Lymphoma Refractory/ Relapsed | Mar 2028 |
| Cabaletta Bio | CABA-201 CD19-specific chimeric antigen receptor T cells | CD19 | Phase 2 | Idiopathic Inflammatory Myopathy; Systemic Sclerosis; Pemphigus Vulgaris; Generalized Myasthenia Gravis (gMG) … | Jul 2028 |
| Shanghai Ming Ju Biotechnology | Relmacabtagene Autoleucel (JWCAR029) CAR-T cell therapy targeting CD19 | CD19 | Phase 2 | Mantle Cell Lymphoma; Lymphoma, Large B-Cell, Diffuse | Aug 2028 |
| St. Jude Children's Research Hospital | Chimeric antigen receptor (CAR) T cell therapy CAR-T cell therapy targeting B-cell lineage antigen | CD19 | Phase 2 | Acute Lymphoblastic Leukemia | Sep 2028 |
| Seoul National University Hospital | SNUH-CD19-CAR-T Cells CD19-targeted chimeric antigen receptor (CAR) T-cell therapy using genetically modified au | CD19 | Phase 2 | Very High Risk Acute Lymphoblastic Leukemia; Childhood-Onset Systemic Lupus Erythematosus | Dec 2028 |
| Merck & Co. (MSD) | MK-1045 anti-CD19 bispecific antibody (engaging T cells for B-cell acute lymphoblastic leukemia) | CD19 | Phase 2 | Follicular Lymphoma; B-cell Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukaemia; Systemic Lupus Erythematosus … | Jul 2029 |
| Ruijin Hospital | Inaticabtagene autoleucel (Inati-cel; CNCT19) CD19-targeted CAR-T cell therapy | CD19 | Phase 2 | Acute Lymphoblastic Leukemia | Dec 2029 |
| St. Jude Children's Research Hospital | CD19-CAR T cell Infusion CD19-targeted chimeric antigen receptor (CAR) T cell therapy | CD19 | Phase 2 | Acute Lymphoblastic Leukemia | Mar 2030 |
| Bristol-Myers Squibb | Lisocabtagene Maraleucel (JCAR017) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 2 | Lymphoma, Non-Hodgkin | Sep 2031 |
| John Lister | Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) CAR-T cell therapy targeting CD19 | CD19 | Phase 2 | B-Cell Lymphoma | Aug 2037 |
| National University of Malaysia | Autologous CD19-directed CAR-T cells CD19-targeted chimeric antigen receptor T-cell therapy | CD19 | Phase 2 | Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma | – |
| Chongqing Precision Biotech | Anti-CD19 UCAR-T cells anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Dermatomyositis, Juvenile | Nov 2026 |
| Gilead Sciences | KITE-197 CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Relapsed/Refractory Large B-cell Lymphoma | Nov 2026 |
| Miltenyi Biomedicine | MB-CART19.1 Anti-CD19 CAR T cell therapy | CD19 | Phase 1 | Acute Lymphoblastic Leukemia Recurrent; SLE - Systemic Lupus Erythematosus | Nov 2026 |
| Beijing Mabworks Biotech | MBS303 T-cell bispecific antibody targeting CD19 on B cells | CD19 | Phase 1 | Non-Hodgkin's Lymphoma | Nov 2026 |
| Bioray Laboratories | BRL-201 CD19-targeted CAR-T cell therapy with PD-1 site-specific integration | CD19 | Phase 1 | Non-hodgkin Lymphoma,B Cell | Nov 2026 |
| TG Therapeutics | Azercabtagene zapreleucel (azer-cel) CAR-T cell therapy targeting CD19-expressing B cells | CD19 | Phase 1 | B-cell Mediated Autoimmune Disorders | Dec 2026 |
| Ting Chang, MD | CD19-BCMA Targeted CAR-T Dual CD19-BCMA targeted CAR-T cell therapy | CD19, BCMA | Phase 1 | Myasthenia Gravis | Dec 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | anti-CD19 IL10/IL15 CAR-NK anti-CD19 chimeric antigen receptor NK cells engineered to co-express IL-10 and IL-15 | CD19, IL10, IL15 | Phase 1 | B-cell Non Hodgkin Lymphoma | Dec 2026 |
| PersonGen BioTherapeutics (Suzhou) | LV009 Injection Anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Non-Hodgkin Lymphoma | Dec 2026 |
| Beijing Yongtai Ruike Biotechnology Company | RC19D2 cell injection anti-CD19 chimeric antigen receptor (CAR-T) cell therapy | CD19 | Phase 1 | Recurrent Diffuse Large B-Cell Lymphoma | Dec 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | A-319 CD19xCD3 bispecific antibody (T-cell redirecting) | CD19, CD3E | Phase 1 | Systemic Lupus Erythematosus | Dec 2026 |
| University of Alberta | Anti-CD19/4-1BB/CD3ζ CAR T-cell anti-CD19 CAR-T cell with 4-1BB and CD3ζ co-stimulatory domains | CD19 | Phase 1 | Relapsed Non Hodgkin Lymphoma | Dec 2026 |
| The First Affiliated Hospital of Soochow University | CART-138/BCMA/19/more Multi-antigen CAR-T cell therapy targeting CD138, BCMA (TNFRSF17), CD19, and additional an | CD138, TNFRSF17, CD19 | Phase 1 | Multiple Myeloma | Dec 2026 |
| Beijing GoBroad Hospital | CD19 CAR-T cells anti-CD19 chimeric antigen receptor T cells | CD19 | Phase 1 | Autoimmune Diseases; Systemic Lupus Erythematosus (SLE) | Dec 2026 |
| Ningbo No. 1 Hospital | CD19-7×19 CAR-T CD19-targeting CAR-T cells engineered to express IL-7 and CCL19 | CD19 | Phase 1 | Diffuse Large B-cell Lymphoma | Dec 2026 |
| Baylor College of Medicine | CD19.CAR/28ζ T cells Anti-CD19 CAR-T cell therapy with CD28 costimulatory domain | CD19 | Phase 1 | Non-Hodgkin Lymphoma | Dec 2026 |
| University of Colorado, Denver | CD19x22 CAR T Cells Dual-targeted CAR T cell therapy against CD19 and CD22 | CD19, CD22 | Phase 1 | Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| Cullinan Therapeutics | CLN-978 CD19-directed T cell engager | CD19 | Phase 1 | NHL; SLE; Rheumatoid Arthritis (RA; Sjögren | Dec 2026 |
| Rong Tao | KQ-2002 CAR-T cells anti-CD19/CD22 CAR-T cell therapy | CD19, CD22 | Phase 1 | Acute Lymphoblastic Leukemia, in Relapse | Dec 2026 |
| Orna Therapeutics | ORN252 circular RNA encoding anti-CD19 CAR protein in lipid nanoparticle | CD19 | Phase 1 | Healthy Volunteers - Male and Female | Dec 2026 |
| Excyte Biopharma | YK012 Bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediate | CD19, CD3 | Phase 1 | Primary Membranous Nephropathy; B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus (SLE); Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Dec 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | anti-CD19 CAR-NK (CB CAR-NK019) anti-CD19 CAR-expressing cord blood-derived NK cells | CD19 | Phase 1 | B-cell Non Hodgkin Lymphoma | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | therapeutic autologous lymphocytes CAR-T cells genetically targeted to CD19 antigen on B cells | CD19 | Phase 1 | Leukemia | Dec 2026 |
| Essen Biotech | BCMA/CD19 CAR-T cells chimeric antigen receptor T cells targeting BCMA and/or CD19 | BCMA, CD19 | Phase 1 | Autoimmune Diseases | Dec 2026 |
| Medical University of South Carolina | CD19-CD34t metabolically programmed CAR transduced T-cells CD19-directed chimeric antigen receptor (CAR) T-cell therapy with metabolic programming an | CD19 | Phase 1 | B-cell Non Hodgkin Lymphoma | Dec 2026 |
| Tongji Hospital | CT1190B anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | B-Cell Non-Hodgkin Lymphoma | Dec 2026 |
| Beijing GoBroad Hospital | Donor-derived CD19 CAR T cells CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| The Children's Hospital of Zhejiang University School of Medicine | anti-CD19-CAR-T cells CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | Systemic Lupus Erythematosus | Dec 2026 |
| Chinese PLA General Hospital | Allogenic CD19-targeting CAR-γδT cell CD19-targeting CAR-γδT cell therapy with second-generation anti-CD19 CAR containing FMC63 | CD19 | Phase 1 | Non Hodgkin's Lymphoma | Dec 2026 |
| Ohio State University Comprehensive Cancer Center | Autologous Anti-CD19/CD20/CD22 CAR T-cells Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22 | CD19, CD20, CD22 | Phase 1 | Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | Dec 2026 |
| Caribou Biosciences | CB-010 CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Lymphoma, Non-Hodgkin | Dec 2026 |
| Chongqing Precision Biotech | CD19 and CD22 targeted prime CAR-T cells CAR-T cell therapy targeting CEA (CEACAM5) | CD19, CEACAM5 | Phase 1 | B-ALL; Advanced Lung Cancer; Systemic Lupus Erythematosus | Dec 2026 |
| Liping Dou | CD22/CD19 Dual-Target CAR-T Cells Dual-target CAR-T cell therapy targeting CD22 and CD19 antigens | CD22, CD19 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | CT1192 Dual CD19/CD20-targeting CAR-T cell therapy | CD19, CD20 | Phase 1 | Systemic Lupus Erythematosus (SLE) | Dec 2026 |
| Nanjing University School of Medicine | FKC289 Dual-targeted BCMA/CD19 CAR-T cell therapy | BCMA, CD19 | Phase 1 | Lupus Nephritis | Dec 2026 |
| Chongqing Precision Biotech | MC-1-50 CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | B Cell Lymphoma; Systemic Lupus Erythematosus (SLE) | Dec 2026 |
| Peking University People's Hospital | Nanobody-Based CD19/CD22 Tandem Dual CAR-T Nanobody-based dual CAR-T cells targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Dec 2026 |
| Pell Bio-Med Technology | PL001 CD19-targeted chimeric antigen receptor T-cell (CAR-T) | CD19 | Phase 1 | Diffuse Large B Cell Lymphoma | Dec 2026 |
| The First Affiliated Hospital of Soochow University | RN1201 Injection CD19 and BCMA-targeted allogeneic CAR-T cells | CD19, BCMA | Phase 1 | Multiple Myloma; Refractory Immune-mediated Platelet Transfusion Refractoriness | Jan 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | universal allogeneic anti-CD19/BCMA CAR T-cells dual-targeting CAR-T cell therapy targeting CD19 and BCMA | CD19, BCMA | Phase 1 | Autoimmune Hemolytic Anemia | Jan 2027 |
| Memorial Sloan Kettering Cancer Center | 19-28z chimeric receptor gene-modified T cells Anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Leukemia; Non-Hodgkin's Lymphoma | Jan 2027 |
| Jiangsu Topcel-KH Pharmaceutical | Anti-PD1 armored CD19 CAR-T cells Anti-PD1 armored CD19 CAR-T cell therapy | CD19, PDCD1 | Phase 1 | Diffuse Large B Cell Lymphoma | Jan 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | CD19/BCMA CAR-T cell therapy Dual-targeted CAR-T cell therapy against CD19 and BCMA | CD19, BCMA | Phase 1 | Systemic Lupus Erythematosus | Jan 2027 |
| Ottawa Hospital Research Institute | CLIC-1901 anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Acute Lymphoblastic Leukemia | Jan 2027 |
| Shanghai Unicar-Therapy Bio-medicine Technology | ssCART-19 CAR-T cell therapy targeting CD19 on B-cell malignancies | CD19 | Phase 1 | B Cell Lymphoma | Jan 2027 |
| Gracell Biotechnologies (Shanghai) | GC012F BCMA/CD19 dual CAR-T cell therapy | TNFRSF17, CD19, BCMA | Phase 1 | Multiple Myeloma; Refractory Systemic Lupus Erythematosus; Relapsed/Refractory AL Amyloidosis | Feb 2027 |
| Essen Biotech | EB-BH2024 (CD19/CD22-CAR T cells) CD19/CD22-targeted chimeric antigen receptor T cells | CD19, CD22 | Phase 1 | Acute Lymphoblastic Leukemia, Adult B-Cell | Feb 2027 |
| University College, London | KCAT19 T cells Allogeneic T cells expressing chimeric antigen receptor targeting CD19 | CD19 | Phase 1 | Blood Cancer | Feb 2027 |
| Kali Therapeutics | KT501 Monoclonal antibody targeting CD19, BCMA and CD3 to deplete B cells and plasma cells | CD19, BCMA, CD3 | Phase 1 | Rheumatoid Arthritis (RA) | Feb 2027 |
| Bruce Cree | KYV-101 CD19-targeted CAR T-cell therapy | CD19 | Phase 1 | Progressive Multiple Sclerosis | Feb 2027 |
| Chinese PLA General Hospital | TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T c Allogeneic CAR-T cell therapy targeting CD19 with TCR alpha/beta chain (TRAC) and SPPL3 ge | TRBC, SPPL3, CD19, TCRA | Phase 1 | Acute Lymphocytic Leukemia; Non-hodgkin Lymphoma | Feb 2027 |
| Memorial Sloan Kettering Cancer Center | 19(T2)28z1xx TRAC CAR T cells CD19-targeted CAR-T cell therapy with 28z costimulatory domain | CD19 | Phase 1 | B-Cell Lymphoma; Diffuse Large B Cell Lymphoma | Feb 2027 |
| Medical College of Wisconsin | CAR-20/19-T cells Chimeric antigen receptor T cells targeting CD20 and CD19, expanded with IL-7/IL-15 | CD20, CD19 | Phase 1 | Non Hodgkin Lymphoma (NHL) | Feb 2027 |
| Chinese PLA General Hospital | Allogenic CD19-CAR-γδT cell (QH103E) CD19-targeting CAR-γδT cell therapy with gene editing for resistance to alloreactive killi | CD19 | Phase 1 | Non-hodgkin Lymphoma,B Cell | Mar 2027 |
| City of Hope Medical Center | Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes CAR-T cell therapy targeting CD19 with CD28 costimulatory domain and EGFRt safety switch | CD19 | Phase 1 | Recurrent Diffuse Large B-Cell Lymphoma; B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma | Mar 2027 |
| City of Hope Medical Center | autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells CD19-directed chimeric antigen receptor (CAR) T cell with CD28 and CD3zeta costimulatory d | CD19 | Phase 1 | Recurrent Diffuse Large B-Cell Lymphoma; Adult Grade III Lymphomatoid Granulomatosis | Mar 2027 |
| Beijing Biotech | Autologous anti-CD19 CAR-T cells CAR-T cell therapy targeting CD19-expressing B cells | CD19 | Phase 1 | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS; Scleroderma, Systemic | Mar 2027 |
| ImmunityBio | CD19t-haNK suspension CAR-T cell therapy targeting CD19; engineered NK-92 cell line expressing CD19-directed CAR | CD19 | Phase 1 | Non Hodgkin's Lymphoma Refractory/Relapsed | Mar 2027 |
| Memorial Sloan Kettering Cancer Center | EGFRt/19-28z/4-1BBL CAR T cells CD19-targeting CAR T cell therapy with 28z costimulatory domain and 4-1BB ligand; EGFRt se | CD19, EGFR | Phase 1 | Chronic Lymphocytic Leukemia (CLL) | Mar 2027 |
| GenomeFrontier Therapeutics TW | GF-CART01 CD20/CD19-targeting CAR T cell therapy | CD20, CD19 | Phase 1 | Diffuse Large B Cell Lymphoma Relapsed | Mar 2027 |
| University Hospital Tuebingen | MB-CART2219.1 CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Lymphoma | Mar 2027 |
| Zhujiang Hospital | CD19 CAR-T cells Anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Acute Lymphoblastic Leukemia | Mar 2027 |
| Chinese PLA General Hospital | Allogeneic CD19-STAR T cell Allogeneic T cells with TRAC locus-inserted CD19-targeting synthetic TCR, with endogenous | CD19, TRAC | Phase 1 | Non-hodgkin Lymphoma,B Cell | Mar 2027 |
| Hebei Senlang Biotechnology | Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells Multi-target CAR-T cells targeting CD19, CD20, and CD22 | CD19, CD22, CD20 | Phase 1 | 19 and 22+ B Cell Hematologic Tumors | Mar 2027 |
| Roche | Englumafusp alfa CD19-targeted 4-1BB ligand | CD19, TNFSF14 | Phase 1 | Lymphoma, Non-Hodgkin | Mar 2027 |
| Shanghai AbelZeta | Prizloncabtagene autoleucel 4-1BB bispecific CAR-T cell targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Relapsed/Refractory Large B-Cell Lymphoma | Mar 2027 |
| The University of Texas Health Science Center at San Antonio | Loncastuximab Anti-CD19 antibody-drug conjugate | CD19 | Phase 1 | Diffuse Large B-cell Lymphoma | Apr 2027 |
| Chinese PLA General Hospital | SL1617 Injection In vivo CD19/CD20-targeted CAR T-cell immunotherapy utilizing engineered lentiviral vector | CD19, CD20 | Phase 1 | B-cell Lymphoma | Apr 2027 |
| Beijing GoBroad Hospital | umbilical cord blood CD19-BCMA CAR-T cells dual-targeted CAR-T cell therapy targeting CD19 and BCMA | CD19, BCMA, CD5, CD7 | Phase 1 | Refractory Lupus Nephritis; T-Cell Non-Hodgkin Lymphoma | Apr 2027 |
| iCell Gene Therapeutics | BCMA-CD19 cCAR T cells Dual-targeted CAR T cell therapy targeting BCMA and CD19 expressed on B cells and plasma c | BCMA, CD19 | Phase 1 | Multiple Myeloma in Relapse; Refractory Immune Cytopenia | Apr 2027 |
| Stanford University | KYV-101 anti-CD19 CAR-T cell therapy anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Dermatomyositis; Multiple Sclerosis | Apr 2027 |
| Nkarta | NKX019 CD19-directed CAR NK cell therapy | CD19 | Phase 1 | Lupus Nephritis; Systemic Sclerosis; Lymphoma, Non-Hodgkin | Apr 2027 |
| Therorna | TI-0032-III injection Lipid nanoparticle-formulated circular RNA encoding CD19 chimeric antigen receptor (CAR) | CD19 | Phase 1 | Systemic Lupus Erythematosus (SLE) | May 2027 |
| Ruijin Hospital | ABO2203 mRNA encoding CD19/CD3 T cell engager | CD19, CD3E | Phase 1 | B-cell Non-Hodgkin Lymphoma | May 2027 |
| University of California, Davis | CD19 Chimeric Antigen Receptor T Cells CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | Recurrent Diffuse Large B-Cell Lymphoma | May 2027 |
| Memorial Sloan Kettering Cancer Center | modified T cells CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | Relapsed B-Cell Acute Lymphoblastic Leukemia | May 2027 |
| Beijing GoBroad Hospital | Dual-targeting BCMA-CD19 CAR-T cell Dual-target CAR-T cell therapy targeting BCMA and CD19 | BCMA, CD19 | Phase 1 | Relapsed or Refractory Multiple Myeloma (RRMM) | May 2027 |
| Chinese PLA General Hospital | CAR19TIF cells BCOR and ZC3H12 genes knock-out CD19-targeting CAR-T cells | CD19 | Phase 1 | Acute Lymphocytic Leukemia; B Cell Lymphoma | May 2027 |
| The First Affiliated Hospital of Xiamen University | GB5005 chimeric antigen receptor T-cell injection anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Non-hodgkin Lymphoma | May 2027 |
| Imugene | Azer-cel (PBCAR0191) Allogeneic anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Non-Hodgkin Lymphoma | Jun 2027 |
| Vironexis Biotherapeutics | VNX-101 Adeno-associated viral vector encoding CD3/CD19 bi-specific T-cell engager | CD3, CD19 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Jun 2027 |
| City of Hope Medical Center | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes CAR-T cell therapy targeting CD19 with CD28 and CD3zeta signaling domains, EGFRt transgene | CD19 | Phase 1 | B Acute Lymphoblastic Leukemia | Jun 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 7x19 CAR-T anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Primary Mediastinal B-cell Lymphoma (PMBCL) | Jun 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | CD19-CAR novel oncolytic vaccinia virus (RGV005) anti-CD19 CAR-NK cells derived from cord blood | CD19 | Phase 1 | Primary Mediastinal B-cell Lymphoma (PMBCL); Refractory/Relapsed B-cell Lymphoma | Jun 2027 |
| Bambino Gesù Hospital and Research Institute | CD19-CAR_Lenti_ALLO allogeneic CD19-directed chimeric antigen receptor T cell therapy | CD19 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Jun 2027 |
| The First Affiliated Hospital with Nanjing Medical University | CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product Dual-target CAR-T cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Relapsed/Refractory B-cell Malignancies | Jun 2027 |
| University of Colorado, Denver | UCD19 CAR T cells anti-CD19 chimeric antigen receptor-expressing (CAR) T cells | CD19 | Phase 1 | Acute Lymphoid Leukemia | Jun 2027 |
| Sumithira Vasu | Anti-CD19/CD20/CD22 CAR T-Cells Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22 | CD19, CD20, CD22 | Phase 1 | Recurrent Acute Lymphoblastic Leukemia | Jul 2027 |
| St. Jude Children's Research Hospital | CD19-CAR(Mem) T-cells Allogeneic CD19-CAR.CD45RA-negative T-cells with 41BBz costimulatory domain | CD19 | Phase 1 | Acute Lymphoblastic Leukemia, in Relapse | Jul 2027 |
| National Cancer Institute (NCI) | CD19/CD22-CAR-transduced T cells bicistronic CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 1 | B-NHL | Jul 2027 |
| University of Utah | Anti-CD19 CAR-T cells anti-CD19 chimeric antigen receptor T cells (CAR-T) | CD19 | Phase 1 | Acute Lymphoblastic Leukemia | Jul 2027 |
| King Faisal Specialist Hospital & Research Center | CD19 CAR T cells chimeric antigen receptor T cells targeting CD19 | CD19 | Phase 1 | Relapsed Refractory Acute Lymphoblastic Leukemia | Jul 2027 |
| The First Affiliated Hospital of Air Force Medical University | CD19 CAR-T cell therapy CD19-directed chimeric antigen receptor T-cell therapy | CD19 | Phase 1 | Refractory Membranous Nephropathy | Jul 2027 |
| Chongqing Precision Biotech | CD19-targeted CAR-T CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Juvenile Dermatomyositis | Jul 2027 |
| Marcela V. Maus, M.D.,Ph.D. | CD79b-19 CAR T cells CAR-T cells targeting CD79b and CD19 | CD79B, CD19 | Phase 1 | Non-hodgkin Lymphoma | Aug 2027 |
| The First Affiliated Hospital of Soochow University | CD19-targeted CAR T-cell therapy CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Acute Lymphoblastic Leukemia With Failed Remission | Aug 2027 |
| Fondazione Matilde Tettamanti Menotti De Marchi Onlus | CARCIK-CD19 Allogeneic cytokine-induced killer cells transduced with CD19 chimeric antigen receptor (C | CD19 | Phase 1 | B-cell NHL | Sep 2027 |
| CytoCares | CC312 anti-CD19 monoclonal antibody | CD19 | Phase 1 | Non-hodgkin Lymphoma; SLE - Systemic Lupus Erythematosus | Sep 2027 |
| Vinmec Research Institute of Stem Cell and Gene Technology | Autologous CD19-Targeted CAR-T Cells CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | Refractory Systemic Lupus Erythematosus | Sep 2027 |
| Iksuda Therapeutics | IKS03 anti-CD19 antibody-drug conjugate with pyrrolobenzodiazepine cytotoxic payload | CD19 | Phase 1 | B-cell Non-Hodgkin Lymphoma | Sep 2027 |
| Memorial Sloan Kettering Cancer Center | In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes Allogeneic EBV-specific T cells genetically modified to express CAR targeting CD19 | CD19, EBNA1, EBNA2, EBNA3 | Phase 1 | Acute Lymphocytic Leukemia | Sep 2027 |
| Stephan Grupp MD PhD | Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19) CD19-directed CAR-T cell therapy | CD19 | Phase 1 | B Cell Acute Lymphoblastic Leukemia (B-ALL); B-cell Acute Lymphoblastic Leukemia | Sep 2027 |
| City of Hope Medical Center | Autologous Anti-CD19 CAR-expressing T Lymphocytes anti-CD19 chimeric antigen receptor (CAR) T-cell therapy | CD19 | Phase 1 | B Acute Lymphoblastic Leukemia | Sep 2027 |
| The Children's Hospital of Zhejiang University School of Medicine | CD19 Universal CAR-T cells anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Systemic Lupus Erythematosus | Sep 2027 |
| Hinge Bio | HB2198 Tetravalent bispecific anti-CD19/CD20 antibody with dual Fc domains | CD19, CD20 | Phase 1 | Healthy Volunteer; Systemic Lupus Erthematosus (SLE) | Oct 2027 |
| Bangdong Gong | iC9/CAR19/IL15 CB-NK cell Chimeric Antigen Receptor Natural Killer Cell targeting CD19 with inducible suicide gene ( | TNFRSF9, CD19, IL15 | Phase 1 | Primary Sjogren's Syndrome | Oct 2027 |
| Bristol-Myers Squibb | Lisocabtagene Maraleucel (JCAR017) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 1 | Leukemia, Lymphocytic, Chronic, B-Cell; Recurrent Transformed Chronic Lymphocytic Leukemia; Lymphoma; Refractory Aggressive B-cell Lymphomas … | Nov 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | CD19 CAR-T cell infusion CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | Systemic Lupus Erythematosus | Dec 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | CD19 Universal CAR-γδT Cells Anti-CD19 CAR-γδT cell therapy | CD19 | Phase 1 | Systemic Lupus Erythematosus | Dec 2027 |
| Paul Szabolcs | CD3/CD19 negative hematopoietic stem cells Negatively selected hematopoietic stem cells depleted of CD3+ and CD19+ cells | CD3, CD19 | Phase 1 | Idiopathic Pulmonary Fibrosis | Dec 2027 |
| Kali Therapeutics | KT502 Monoclonal antibody targeting CD19 and CD3 for B cell depletion | CD19, CD3 | Phase 1 | Rheumatoid Arthritis (RA) | Dec 2027 |
| Beijing GoBroad Hospital | OL-CD19-GDT CD19-targeting genetically modified T cell therapy | CD19 | Phase 1 | Systemic Sclerosis (SSc) | Dec 2027 |
| Shenzhen University General Hospital | CD19/CD20 CAR/TRuC-T Dual-targeted CAR/TRuC T-cell therapy against CD19 and CD20 | CD19, CD20 | Phase 1 | Relapsed/Refractory B-cell Lymphoma | Dec 2027 |
| Guangzhou Women and Children's Medical Center | CD19/CD22 CAR-T cell therapy Dual-target CAR-T cell therapy targeting CD19 and CD22 using retroviral vector-based tande | CD19, CD22 | Phase 1 | Acute Lymphoblastic Leukemia | Dec 2027 |
| Tongji Hospital | Universal CD19 CAR-γδT Cell Injection (QH103) Allogeneic CD19 CAR-γδT cell therapy | CD19 | Phase 1 | Multiple Sclerosis (MS) | Dec 2027 |
| Grit Biotechnology | GT719 Injection anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Neurological Autoimmune Diseases; Hematological Malignancy (Leukemia- Lymphoma) | Jan 2028 |
| Aibin Liang,MD,Ph.D. | dualCAR-NK19/70 cell anti-CD19/CD70 CAR-NK cell therapy | CD19, CD70 | Phase 1 | Refractory or Relapsed B-cell Non-Hodgkin Lymphoma | Jan 2028 |
| Sanofi | SAR448501/DR-0201 Bispecific antibody targeting CD19 and CD3E | CD19, CD3E | Phase 1 | B-cell Non Hodgkin Lymphoma; Systemic Lupus Erythematosus (SLE) | Jan 2028 |
| TICAROS | TC011 Anti-CD19 chimeric antigen receptor T cell therapy | CD19 | Phase 1 | Relapsed Large B-cell Lymphoma | Feb 2028 |
| Allogene Therapeutics | ALLO-329 Allogeneic dual CAR T-cell therapy targeting CD19 and CD70 | CD19, CD70 | Phase 1 | Systemic Lupus Erythematosus (With and Without Nephritis) | Feb 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | UCAR T-cell universal allogeneic anti-CD19/BCMA CAR T-cells | CD19, BCMA | Phase 1 | Systemic Lupus Erythematosus | Feb 2028 |
| Memorial Sloan Kettering Cancer Center | 19-28z/IL-18 CAR T cells CAR-T cell therapy targeting CD19 with IL-18 co-expression | CD19, IL18 | Phase 1 | Philadelphia-Negative ALL | Feb 2028 |
| City of Hope Medical Center | Anti-CD19-CAR CMV-specific T-lymphocytes CMV-specific CD19 CAR-T cells | CD19 | Phase 1 | B-Cell Non-Hodgkin Lymphoma; High Grade B-Cell Non-Hodgkin's Lymphoma | Mar 2028 |
| Mayo Clinic | Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 CD19-directed CAR-T cell therapy | CD19 | Phase 1 | Recurrent B-Cell Non-Hodgkin Lymphoma | Mar 2028 |
| Ruijin Hospital | Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells Dual-targeted CAR-T cells expressing chimeric antigen receptors against CD19 and CD22 | CD19, CD22 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Mar 2028 |
| TriArm Therapeutics (Taiwan) | ARM011 CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | Acute Lymphoblastic Leukemia | Apr 2028 |
| Chongqing Precision Biotech | PTOC1 CD19-targeted CAR-T cell therapy | CD19 | Phase 1 | Systemic Lupus Erythematosus | Apr 2028 |
| Nelson Hamerschlak | Chimeric antigen receptor T cells Anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Acute Lymphoblastic Leukemia, in Relapse | May 2028 |
| City of Hope Medical Center | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes CD19-CAR T cell therapy with CD28 and CD3zeta costimulatory domains and truncated EGFR saf | CD19 | Phase 1 | Central Nervous System Lymphoma | May 2028 |
| Tianjin Medical University Cancer Institute and Hospital | LUCAR-G39D Dual-targeted CAR-T cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 1 | B-Cell Non-Hodgkin Lymphoma-Recurrent | Jun 2028 |
| Xi'an No.3 Hospital | allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells (UCAR-T) dual-targeting CD19/BCMA CAR-T cell therapy | CD19, BCMA | Phase 1 | Relapsed/Refractory Multiple Myeloma(MM) | Jul 2028 |
| Paul Szabolcs | CD3/CD19 depleted leukocytes Negative selection depleting CD3+ and CD19+ T cells and B cells from donor bone marrow via | CD3E, CD19 | Phase 1 | Sickle Cell Anemia | Aug 2028 |
| Tanabe Pharma | Loncastuximab Tesirine (MT-2111) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 1 | Diffuse Large B-Cell Lymphoma | Aug 2028 |
| Memorial Sloan Kettering Cancer Center | MB-CART19.1 CD19-directed CAR-T cell therapy | CD19 | Phase 1 | Primary Central Nervous System (CNS) Lymphoma | Aug 2028 |
| Chulalongkorn University | CMD63 CD19-targeted CAR-T cell with IL-7Rα signaling domain | CD19, IL7R | Phase 1 | Relapse B Acute Lymphoblastic Leukemia | Sep 2028 |
| UCARsgen Biotech Limited | CT1190B CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Large B-Cell Lymphoma (LBCL) | Sep 2028 |
| Peking University Cancer Hospital & Institute | LUCAR-20SP CD19-directed CAR-T cell therapy | CD19 | Phase 1 | Relapsed B-cell Non-Hodgkin Lymphoma | Sep 2028 |
| Institut de Recherches Internationales Servier | UCART19 allogeneic CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Advanced Lymphoid Leukemia | Sep 2028 |
| Seattle Children's Hospital | SCRI-CAR19v3 CD19-targeting CAR-T cell therapy | CD19 | Phase 1 | Systemic Lupus Erythematosus | Oct 2028 |
| Chinese PLA General Hospital | BEX101 injection anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Non-Hodgkin's Lymphoma | Oct 2028 |
| National University Hospital, Singapore | Epo-R-CD19 CAR T CAR-T cell therapy targeting CD19 and Epo-R expressing B cell lymphoma cells | ERBB2, CD19 | Phase 1 | B-cell Lymphoma Refractory | Oct 2028 |
| Antengene Biologics | ATG-201 Bispecific T-cell engager (TCE) binding CD3 and CD19 | CD3, CD19 | Phase 1 | Systemic Lupus Erythematosus | Dec 2028 |
| Myeloid Therapeutics | CRT-402 CD19-targeted CAR-T cell therapy designed to deplete CD19-positive B cells | CD19 | Phase 1 | Autoimmune Diseases | Dec 2028 |
| Chinese PLA General Hospital | KSVCBD injection in vivo CAR-T therapy targeting CD19 and BCMA | CD19, BCMA | Phase 1 | Multiple Myeloma; Non-Hodgkin's Lymphoma | Dec 2028 |
| The Children's Hospital of Zhejiang University School of Medicine | UCAR T-cell Universal allogeneic anti-CD19/BCMA CAR T-cells | CD19, BCMA | Phase 1 | Autoimmune Diseases | Dec 2028 |
| National Institute of Allergy and Infectious Diseases (NIAID) | huCART19 Humanized Chimeric Antigen Receptor T cell targeting CD-19 | CD19 | Phase 1 | Kidney Transplant | Dec 2028 |
| National Cancer Institute (NCI) | Anti-CD19 and anti-CD20 bicistronic CAR T cells bicistronic CAR T cells targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Chronic Lymphocytic Leukemia | Dec 2028 |
| TCRx Therapeutics Co.Ltd | KSV01 Injection CD19-targeted CAR-T cell therapy using lentiviral vector | CD19 | Phase 1 | Non-Hodgkin Lymphoma; B-ALL | Dec 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | QT-019C universal allogeneic anti-CD19/BCMA CAR T-cells | CD19, BCMA | Phase 1 | SLE - Systemic Lupus Erythematosus | Jan 2029 |
| Abramson Cancer Center at Penn Medicine | anti-CD19 CAR-T CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Large B Cell Lymphoma | Jan 2029 |
| Allogene Therapeutics | ALLO-501A Anti-CD19 allogeneic CAR T cell therapy | CD19 | Phase 1 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Feb 2029 |
| Bristol-Myers Squibb | BMS-986515 CD19-targeted allogeneic CAR T cell therapy | CD19 | Phase 1 | Refractory Autoimmune Diseases | Mar 2029 |
| Poseida Therapeutics | P-CD19CD20-ALLO1 Allogeneic CAR-T cells targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Mar 2029 |
| Umoja Biopharma | UB-VV111 CD19 CAR T cell therapy generated in vivo via gene therapy | CD19 | Phase 1 | Lymphoma, B-Cell | Mar 2029 |
| University College, London | BCMA/CD19 CAR T cells CAR T cells co-expressing BCMA and CD19 CARs | BCMA, CD19 | Phase 1 | Multiple Myeloma | Mar 2029 |
| Shenzhen University General Hospital | CD19-CAR.p40-T CD19-targeted CAR-T cell expressing autocrine IL-40 | CD19 | Phase 1 | B Cell Lymphoma | Apr 2029 |
| AvenCell Therapeutics | Allo-QuadCAR01-T Allogeneic CAR-T cell therapy targeting CD19/CD20 | CD19, CD20 | Phase 1 | Lymphoma Diffuse Large B-cell | Apr 2029 |
| Shanghai Exuma Biotechnology | C402-CD19-CAR Anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Diffuse Large B-cell-lymphoma | Apr 2029 |
| University of Texas Southwestern Medical Center | CAR-T cell therapy CD19-directed chimeric antigen receptor T-cell therapy | CD19 | Phase 1 | Non Hodgkin Lymphoma | May 2029 |
| Gilead Sciences | KITE-363 CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Chronic Inflammatory Demyelinating Polyneuropathy; Relapsed and/or Refractory B-cell Lymphoma | Jun 2029 |
| National Cancer Institute (NCI) | Autologous HuCD19 (Anti-CD19) CAR T cells Anti-CD19 chimeric antigen receptor T-cell immunotherapy | CD19 | Phase 1 | Leukemia, Lymphocytic, Chronic, B-Cell | Jul 2029 |
| University Hospital, Lille | autologous anti-CD19 CAR-T cells anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Relapsed Adult AML | Jul 2029 |
| Baylor College of Medicine | CD19CAR-28-zeta T cells CD19-targeted chimeric antigen receptor (CAR) T cell therapy with CD28 costimulatory domai | CD19 | Phase 1 | B Cell Lymphoma | Jul 2029 |
| Instituto de Investigación Biomédica de Salamanca | TranspoCART19 Anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Refractory B-Cell Lymphoma | Jul 2029 |
| Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | GN001 CD19-targeted CAR T cell therapy delivered via lentiviral vector | CD19 | Phase 1 | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Aug 2029 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 7×19-THEMIS CAR-T cells IL7 and CCL19-armed anti-CD19 CAR-T cell therapy with Themis coexpression | CD19 | Phase 1 | Relapsed/Refractory Large B-cell Lymphoma (LBCL) | Sep 2029 |
| Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | TranspoCART19 CD19-directed CAR-T cell therapy | CD19 | Phase 1 | Lupus Nephritis | Sep 2029 |
| Seattle Children's Hospital | Autologous CD19 CAR+ EGFTt + T cells CD19-directed CAR-T cell therapy with EGFRt safety tag | CD19 | Phase 1 | B Cell Leukemia | Jan 2030 |
| St. Jude Children's Research Hospital | CD19-CD22 CAR T cell bispecific CAR T cell targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Acute Lymphoblastic Leukemia | Jan 2030 |
| CRISPR Therapeutics | CTX112 (Zugocabtagene geleucel, zugo-cel) CD19-directed CAR-T cell therapy; allogeneic T cells genetically modified using CRISPR-Cas | CD19 | Phase 1 | B-cell Lymphoma; Warm Autoimmune Hemolytic Anemia (WAIHA) | Jan 2030 |
| Children's Hospital of Philadelphia | CART19 Anti-CD19 chimeric antigen receptor T cell expressing scFv:41-BB:TCRζ | CD19 | Phase 1 | SLE | Feb 2030 |
| University of Colorado, Denver | CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells CD19-directed CAR-T cell therapy with 4-1BB costimulatory domain | CD19 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Mar 2030 |
| AbClon | AT101 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy | CD19 | Phase 1 | B-cell Non Hodgkin Lymphoma | Mar 2030 |
| Arovella Therapeutics | ALA-101 anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Non Hodgkin Lymphoma (NHL) | Mar 2030 |
| Instituto de Investigación Hospital Universitario La Paz | Autologous CD19/CD22 CAR T cells Anti-CD19/CD22 chimeric antigen receptor T cell therapy | CD19, CD22 | Phase 1 | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Jun 2030 |
| Curocell | CRC01 anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Relapsed Large B-cell Lymphoma | Aug 2030 |
| National Cancer Institute (NCI) | mCD19-CAR-CD28-CD3-zeta (anti-CD19 CAR) anti-CD19 CAR-T cell therapy with CD28 and CD3-zeta costimulatory domains | CD19 | Phase 1 | Hematologic Malignancies | Nov 2030 |
| Baylor College of Medicine | CD19.CAR-CD28Z T Cells CAR-T cells targeting CD19 with CD28 costimulatory domain | CD19 | Phase 1 | Non-Hodgkin's Lymphoma | Dec 2030 |
| Baylor College of Medicine | CD19CAR/virus specific T cells chimeric antigen receptor (CAR) T cells targeting CD19 | CD19 | Phase 1 | Acute Lymphoblastic Leukemia (ALL) | Apr 2031 |
| St. Jude Children's Research Hospital | CD45RA-depleted CD19-CAR T cells CD19-directed chimeric antigen receptor T cell therapy | CD19 | Phase 1 | Relapsed Pediatric ALL | Dec 2031 |
| CRISPR Therapeutics | CTX112 CD19-directed allogeneic T-cell therapy with CRISPR-Cas9 gene editing | CD19 | Phase 1 | SLE (Systemic Lupus) | Dec 2031 |
| Roche | P-CD19CD20-ALLO1 allogeneic CAR-T cell therapy targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Multiple Sclerosis | Aug 2032 |
| University College, London | CD19CAR T-cells anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Primary CNS Lymphoma | Dec 2032 |
| Loyola University | CD19-CD34 CAR transduced T cells CAR-T cells targeting CD19 expressed on B cell malignancies | CD19 | Phase 1 | B-Cell Acute Lymphoblastic Leukemia, Adult | Dec 2034 |
| Seattle Children's Hospital | Patient-derived CD19- and CD22 specific CAR T-cells Dual-specificity CAR-T cells targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Leukemia | Mar 2035 |
| Takara Bio | TBI-1501 anti-CD19 chimeric antigen receptor (CAR)-T cell therapy | CD19 | Phase 1 | Lymphoblastic Leukemia, Acute Adult | Mar 2035 |
| Stanford University | CD19/CD22 Chimeric Antigen Receptor T-Cell Therapy CAR T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 1 | B Acute Lymphoblastic Leukemia | Aug 2035 |
| Benjamin Tomlinson | Anti-CD19 Chimeric Antigen Receptor T Cells CAR-T cells targeting CD19 | CD19 | Phase 1 | Non-Hodgkin Lymphoma | Feb 2036 |
| Seattle Children's Hospital | Patient Derived CD19 specific CAR T cells with EGFRt CD19-directed CAR-T cell therapy with 4-1BB costimulatory domain and truncated EGFR marker | CD19 | Phase 1 | CD19+ Acute Leukemia | Jul 2036 |
| Seattle Children's Hospital | SCRI-huCAR19v1 CD19-specific CAR T cell therapy with fully human binding domain, 4-1BB-ζ costimulatory do | CD19 | Phase 1 | Leukemia | Dec 2036 |
| Seattle Children's Hospital | SCRI-huCAR19v2 CD19-specific CAR T cell therapy with fully human binding domain, 4-1BB-ζ costimulatory do | CD19 | Phase 1 | Leukemia | Dec 2036 |
| UNC Lineberger Comprehensive Cancer Center | iC9-CAR19 T cells Anti-CD19 chimeric antigen receptor (CAR) T cells with inducible caspase 9 safety switch | CD19 | Phase 1 | Acute Lymphoblastic Leukemia; Lymphoma | Sep 2037 |
| Baylor College of Medicine | CD19.CAR-aNKT cells CD19-targeted chimeric antigen receptor (CAR) allogeneic natural killer T (NKT) cells | CD19 | Phase 1 | Refractory B-Cell Non-Hodgkin Lymphoma | May 2040 |
| Seattle Children's Hospital | second generation 4-1BBζ EGFR806-EGFRt Dual-targeting CAR-T cell therapy against EGFR and CD19 with 4-1BB costimulation | EGFR, CD19 | Phase 1 | Pediatric Solid Tumor | Jun 2040 |
| The First Affiliated Hospital of Soochow University | ssCART-19 cells combined with CD19+ feeding T cells (FTCs) CD19-directed CAR-T cell therapy combined with CD19+ engineered T cells to enhance CAR-T e | CD19 | Phase 1 | Acute Lymphoblastic Leukemia, Adult B-Cell | Jul 2040 |
| Benjamin Tomlinson | Fully human anti-CD19 CAR-T cells Anti-CD19 chimeric antigen receptor T cell therapy | CD19 | Phase 1 | Non Hodgkin Lymphoma | Dec 2040 |
| Seattle Children's Hospital | second generation 4-1BBζ B7H3-EGFRt-DHFR Dual-targeted CAR T cell therapy directed at B7H3 and CD19 with 4-1BB costimulatory domain | B7H3, CD19 | Phase 1 | Pediatric Solid Tumor | Dec 2040 |
| Melody Smith | Allogeneic donor-derived CD19/CD22-CAR T cells bivalent CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Lymphoid Leukemia | Dec 2045 |
| Chinese PLA General Hospital | ATHENA CAR-T (TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting Anti-CD19 CAR-T cell therapy with TRAC and SPPL3 gene knockout in allogeneic T cells | CD19 | Phase 1 | Non Hodgkin's Lymphoma | – |
| Vitebsk Regional Clinical Cancer Centre | Anti-CD19 CAR T-cell therapy anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Chronic Lymphocytic Leukaemia (CLL) | – |
| Institute of Hematology and Blood Transfusion, Czech Republic | Autologous CAR19 T lymphocytes CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | – |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | CD19-CAR_Lenti anti-CD19 CAR T-cell therapy | CD19 | Phase 1 | Lupus Erythematosus, Systemic | – |
| Shenzhen University General Hospital | CD19/CD20-CAR.p40-T Dual-targeting CD19/CD20 chimeric antigen receptor T cell therapy | CD19, CD20 | Phase 1 | Relapsed/Refractory B-cell Lymphoma | – |
| Institute of Hematology & Blood Diseases Hospital, China | CNCT19 Second-generation CAR-T cell therapy targeting CD19 with 4-1BB/CD3-ζ costimulatory domain | CD19 | Phase 1 | Autoimmune Hemolytic Anemia | – |
| Zhejiang University | CNCT19 anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Advanced Hepatocellular Carcinoma | – |
| Han weidong | Decitabine-primed Tandem CAR19/20 engineered T cells Tandem CAR-T cell therapy targeting CD19 and CD20, primed with decitabine | CD19, CD20 | Phase 1 | Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | – |
| David Wald | UF-KURE19 CAR-T cells CAR-T cells with scFV targeting CD19 | CD19 | Phase 1 | Non Hodgkin Lymphoma | – |
| Changhai Hospital | anti-CD19 CAR NK cells anti-CD19 chimeric antigen receptor (CAR) NK cell therapy | CD19 | Phase 1 | Autoimmune Diseases | – |
| Miltenyi Biomedicine | anti-CD19 CAR T cell therapy anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Systemic Lupus Erythematosus; Relapse/Refractory B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erthematosus | – |
| C. Babis Andreadis | anti-CD19 CAR-T cells CD19-directed chimeric antigen receptor T-cell therapy | CD19 | Phase 1 | Refractory Non-Hodgkin Lymphoma | – |
Acute Lymphoblastic Leukemia (26) B-cell Acute Lymphoblastic Leukemia (22) Systemic Lupus Erythematosus (21) B Acute Lymphoblastic Leukemia (12) Non-Hodgkin Lymphoma (10) Lymphoma (10) B-cell Non Hodgkin Lymphoma (8) Systemic Lupus Erythematosus (SLE) (8) Large B-cell Lymphoma (8) B Cell Lymphoma (7) Recurrent Diffuse Large B-Cell Lymphoma (7) Leukemia (7)
other (112), mixed (77), protein or peptide (42), small molecule (25), antibody (7)
Chinese PLA General Hospital (10) Memorial Sloan Kettering Cancer Center (8) Seattle Children's Hospital (8) City of Hope Medical Center (7) Institute of Hematology & Blood Diseases Hospital, China (6) The First Affiliated Hospital of Soochow University (6) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (6) Second Affiliated Hospital, Zhejiang University, School of Medicine (5) Gilead Sciences (5) Beijing GoBroad Hospital (5) Baylor College of Medicine (5) Bristol-Myers Squibb (5) Chongqing Precision Biotech (5) St. Jude Children's Research Hospital (5) National Cancer Institute (NCI) (4) University College, London (3) Ruijin Hospital (3) Allogene Therapeutics (3) University of Colorado, Denver (3) Shenzhen University General Hospital (3)
CD22 (24) CD20 (22) BCMA (20) CD3E (7) CD3 (6) TNFRSF17 (4) IL15 (2) CD70 (2) TCRA (2) EGFR (2) IL10 (1) PDCD1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.